NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) On Track to Advance Innovative Products
HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection,” a recent article reads. “Although HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (‘FDA’), the company is ‘on track with our HeartBeam AIMIGo 3D vector ECG first-generation product, which we expect will be ready for FDA submission in Q1 2023, and the anticipated FDA clearance for our HeartBeam AIMI system,’ wrote HeartBeam Founder and CEO Branislav Vajdic, PhD, in a recent shareholder report. ‘We enter 2023 with tremendous momentum and look forward to sharing our accomplishments in the coming year as we strive to create value for our customers, shareholders, employees, and communities.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately; and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection,” a recent article reads. “Although HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (‘FDA’), the company is ‘on track with our HeartBeam AIMIGo 3D vector ECG first-generation product, which we expect will be ready for FDA submission in Q1 2023, and the anticipated FDA clearance for our HeartBeam AIMI system,’ wrote HeartBeam Founder and CEO Branislav Vajdic, PhD, in a recent shareholder report. ‘We enter 2023 with tremendous momentum and look forward to sharing our accomplishments in the coming year as we strive to create value for our customers, shareholders, employees, and communities.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
